195 related articles for article (PubMed ID: 27373506)
1. Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.
De Pauw I; Wouters A; Van den Bossche J; Peeters M; Pauwels P; Deschoolmeester V; Vermorken JB; Lardon F
Pharmacol Ther; 2016 Oct; 166():71-83. PubMed ID: 27373506
[TBL] [Abstract][Full Text] [Related]
2. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
Khelwatty SA; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2011 Aug; 39(2):483-91. PubMed ID: 21617858
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
Modjtahedi H; Cho BC; Michel MC; Solca F
Naunyn Schmiedebergs Arch Pharmacol; 2014 Jun; 387(6):505-21. PubMed ID: 24643470
[TBL] [Abstract][Full Text] [Related]
5. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
6. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
Bowles DW; Weickhardt A; Jimeno A
Drugs Today (Barc); 2013 Sep; 49(9):523-35. PubMed ID: 24086949
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism of action and preclinical development of afatinib].
Diz Taín P; González AL; García-Palomo A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():7-11. PubMed ID: 27426242
[TBL] [Abstract][Full Text] [Related]
8. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
10. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
[TBL] [Abstract][Full Text] [Related]
11. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
[TBL] [Abstract][Full Text] [Related]
12. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
14. Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.
Brands RC; Müller-Richter UD; De Donno F; Seher A; Mutzbauer G; Linz C; Kübler AC; Hartmann S
Mol Med Rep; 2016 Mar; 13(3):2338-44. PubMed ID: 26782932
[TBL] [Abstract][Full Text] [Related]
15. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.
Kwak EL; Shapiro GI; Cohen SM; Becerra CR; Lenz HJ; Cheng WF; Su WC; Robohn M; Le Maulf F; Lobmeyer MT; Chand VK; Iafrate AJ
Cancer; 2013 Aug; 119(16):3043-51. PubMed ID: 23775486
[TBL] [Abstract][Full Text] [Related]
17. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Vidal ÓJ
Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
[TBL] [Abstract][Full Text] [Related]
18. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.
Harbeck N; Solca F; Gauler TC
Future Oncol; 2014 Jan; 10(1):21-40. PubMed ID: 24328407
[TBL] [Abstract][Full Text] [Related]
20. [Evidence on afatinib in patients progressing on a first-line treatment].
Artal Cortés Á; Gimeno Pelegrín J; Alejandro MÁ
Med Clin (Barc); 2016 Apr; 146 Suppl 1():19-24. PubMed ID: 27426244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]